Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis

Journal of Orthopaedic Surgery and Research

Volumn 2, Issue 1, 2007, Pages

  Qin, Ling ^a   Choy, Wingyee ^a   Au, Szeki ^a   Fan, Musei ^a   Leung, Pingchung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249864500     PISSN: None     EISSN: 1749799X     Source Type: Journal    
DOI: 10.1186/1749-799X-2-9     Document Type: Article

References (26)

1. Hung LK, Wu HT, Leung PC, Qin L: Low BMD is a risk factor for 'low energy' Colles' fracture in pre- and postmenopausal women in Hong Kong Chinese -A DXA and pQCT study. Clin Orthop Rel Res 2005, 435:219-25.
2. Cummings SR, Melton LJ: Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359(9319): 1761 -7.
3. Lau EM, Lee JK, Suriwongpaisal P, Saw SM, Das De S, Khir A: The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS). Osteoporos Int 2001, 12(3):239-43.
4. Melton LJ 3rd, Thamer M, Ray NF, Chan JK, Chesnut CH 3rd, Einhorn TA, Johnston CC, Raisz LG, Silverman SL, Siris ES: Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997, 12(1):16-23.
5. Anonymous: Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Executivesummary. Osteoporos Int 1998, 8(4):S3-6.
6. Brown JP, Josse RG: Scientific Advisory Council of the Osteoporosis Society of Canada: Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002, 167(10):S1-34.
7. Christensen PM, Brixen K, Gyrd-Hansen D, Kristiansen IS: Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 2005, 96(5):387-96.
8. Kung AWC, Yeung SS, Chu LW: The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: A randomized placebo-controlled study. Calcif Tissue Int 2000, 67:286-90.
9. Lau EM, Woo J, Chan YH, Griffith J: Alendronate prevents bone loss in Chinese women with osteoporosis. Bone 2000, 27(5):677-80.
10. Morrison LS, Tobias JH: Effect of a case-finding strategy for osteoporosis on bisphosphonate prescribing in primary care. Osteoporosis Int 2005, 16(1):71 -7.
11. Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jonsson B: Intervention thresholds for osteoporosis in the UK. Bone 2005, 36(1):22-32.
12. Qin L, Au SK, Leung PC, Lau MC, Woo J, Choy WY, Hung WY, Dambacher MA, Leung KS: Baseline BMD and bone loss at distal radius measured by peripheral quantitative computed tomography in peri- andpostmenopausal Hong Kong Chinese women. Osteoporos Int 2002, 13:962-970.
13. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB: Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trail. J Bone Miner Res 1998, 13:1431-8.
14. Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M: Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Asse 2002, 6(29):1-146.
15. WHO: Guidelines for preclinical evaluation and clinical trials in osteoporosis. WHO, Geneva; 1998.
16. Bouxsein ML, Parker RA, Greenspan SL: Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women. Osteoporosis Int 1999, 10:505-9.
17. Kohrt WM, Birge SJ Jr: Differential effects of estrogen treatment on bone mineral density of the spine, hip, wrist and total body in late postmenopausal women. Osteoporo Int 1995, 5(3): 150-5.
18. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T: Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104(10):1363-74.
19. Stepan JJ, Alendeld F, Boivin G, Feyen JH, Lakatos P: Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 2003, 37(4):225-38.
20. Downs RW Jr, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, Wang L, Smith ME, Gormely GJ, Melton ME: Comparison of Alendronate and Intranasal Calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000, 85(5): 1783-8.
21. Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, DeBrock J, Ricerca E, Chesnut CH 3rd: The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993, 76(6): 1399-406.
22. Chan K, Qin L, Lau M, Woo J, Au S, Choy W, Lee K, Lee S: A randomized, prospective study of the effects of Tai Chi Chun exercise on bone mineral density in postmenopausal women. Arch Phys MedRehab 2004, 85:717-22.
23. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR: Fracture riskreduction with alendronate in women with osteoporosis: the Fracturelntervention Trail. FIT research group. J Clin Endocrinol Metab 2000, 85(11):4118-24.
24. Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C: Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone 1996, 19(1):9-12.
25. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the fracture intervention trial. JAMA 1998, 280(24):2077-82.
26. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-Sheng G, Galich AM, Vandormael K, Yates AJ, Stych B: Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999, 9(5):461-8.